NEW YORK, NY / ACCESS Newswire / April 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...

With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals (NASDAQ:SUPN) develops and markets treatments for central nervous system ...

Supernus Pharmaceuticals got a positive adjustment to its Relative Strength (RS) Rating, from 67 to 81. Please watch the ...

NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...

StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a strong-buy ...

Swiss National Bank lifted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 0.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities ...

Axsome Therapeutics' experimental drug to treat attention deficit hyperactivity disorder (ADHD) helped improve symptoms of the developmental disorder in adults, it said on Tuesday, meeting the main ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Supernus (SUPN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates ...

Today, we are looking at branded pharmaceuticals stocks, starting with Supernus Pharmaceuticals (NASDAQ:SUPN). The branded pharmaceutical industry relies on a high-cost, high-reward business model ...